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A B S T R A C T
Obesity is chronic disease with multiple health consequences and among the most severe health problems worldwide.
According to public health records around 65% of population in Croatia are overweight and 20% obese. National physi-
cians chamber with support of Health and Social Welfare Ministry gave recommendations on diagnosing and treating of
obesity in form of national consensus. Treatment of obesity is complex and enrolls multiple clinical specialties. Change of
life style, strenuous physical activity and pharmacotherapy are part of conservative treatments. Patients are treated more
efficiently by minimally invasive endoscopic procedures or bariatric surgery depending on starting body mass index
score. Implantation of intragastric balloons is conceptually simple method of obesity treatment. Modern devices as Bio-
Enterics intragastric balloons (BIB®), (Inamed Health, USA) are gaining wide popularity among both patients and phy-
sicians. BIB intragastric offers the best gains with individuals ranging BMI from 35 to 40. Efficiency has relative ti-
meline dependance from 85% at 6 months to 24% at 36 months. BIB offers substantial ameliorative influence on obesity
comorbidities, particularly cardiovascular risk. Treatment with BIB is also efficient but transient treatment modality in
morbidly and superobese individuals to reduce preoperative risks of general and bariatric surgery. Obesity treatment
with BIB is well tolerated and safe, offering better quality of life. Nevertheless, due to relative poor results of conservative
obesity treatments on long term follow up further investigations defining new clinical parameters for solving treatment
resistance. In order to provide resourcefully individualized approach modern perspectives are focused on endocrine con-
stitutes of obesity. Hormonal effects of BIB treatment in compare to bariatric surgery are potentially interesting for the
prospect studies.
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Introduction
Obesity is chronic disease among the most severe
health problems in both developed and transitional civili-
zations. According to Croatian public health records 58.2%
of female and 68.3% of male are overweight (BMI>25
kg/m2), with 22.7% female and 21.6% male being obese
(BMI>30 kg/m2). Even more concerning is the fact that
11% of school age children is overweight and 5% obese.
World Health Organization (WHO) reported global epi-
demic of Obesity in 21st century, tending to outspread to
50% of global population by 20251.
Secondary effects of obesity
Obesity brings multiple consequences on global
health status. It affects functional changes in perfor-
mance of different organs and altering for the worse
quality of life. Series of epidemiological studies have
shown that obesity represents crucial risk factor of im-
paired glucose tolerance, diabetes, dyslypoproteinemia,
cardiovascular diseases and advancement of degenera-
tive changes in musculoskeletal system2–4. Total mortal-
ity is higher in obese patients and significantly correlates
to body mass index BMI (5). Within pathological BMI
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range (25 to 50 kg/m2), a 5 kg/m2 raise in BMI was shown
to be related with a significant increase in mortality
from: coronary artery disease (hazard ratio [HR] 1.39),
cerebrovascular insult (HR 1.39), diabetes (HR 2.16) and
chronic kidney disease (HR 1.59). The mortality from
number of cancers was found to be associated to BMI
(HR 1.10) (liver, kidney, breast, endometrial, prostate,
and colon)5. Swedish Obese Subjects Study showed posi-
tive connection of several comorbidities with BMI excess
(hypertension — 13.6 percent, diabetes mellitus — 6.3
percent, hyperinsulinemia — 6.3 percent, hypertriglyce-
ridemia — 7.7 percent, low serum high-density-lipopro-
tein (HDL) cholesterol concentration — 8.6 percent, hy-
percholesterolemia — 12.1 percent)6.
Main Outcome Measures and Methodology
The body mass index (BMI) is the most commonly
used tool for initial screening giving different grades of
obesity (BMI>25 overweight, BMI 30–34.9 grade I obe-
sity, BMI 35–39.9 grade II obesity, BMI>40 grade III i.e.
morbid obesity, BMI>50 so called »superobesity«)6. The
treatment side is also closely related to initial BMI1.
Waist and hip circumference are especially useful for
detecting »central« adiposity linked to higher mortality
from obesity comorbidities8,9. Waist circumference grea-
ter than 102 cm for men and 88 cm for women was found
to be related with a higher risk for diabetes, dyslipide-
mia, hypertension and coronary disease individuals from
grade I obesity group8.
Absolute weight reduction (AWR) represents weight
reduction in kilograms, representing baseline body wei-
ght minus after-treatment body weight.
Excess body weight (EBW) is the actual weight pre-
-treatment minus the ideal body weight according to the
individual’s height.
Ideal body weight in most of study was defined as BMI
of 25 kg/m2,10,11.
Percentage excess weight reduction (%EWL) is the
percentage reduction in excess body weight after the BIB
treatment, at a given time, it equals absolute weight re-
duction (AWR) divided by excess body weight and at a
given time multiplied by 100.
Percent of excess body mass index loss (%EBL) is the
percentage of BMI change and is calculated as pre-treat-
ment BMI minus post-treatment BMI and divided by
preoperative BMI-25 and multiplied by 10012.
Percentage of loss of total weight (%LTW) represents
percentage of reduction in total weight at a given time
i.e. after BIB treatment, and is calculated as post – treat-
ment weight loss in kilograms divided by pre-treatment
body weight in kilograms and multiplied by 100.
Modern perspectives are focusing on endocrine part of
obesity, considering the gut as hormone factory; »the
home of hormones« and potentially interesting from
therapeutic view13.
There is still relatively insufficient knowledge in re-
gard to adequate methodology for treatment analysis
and long term follow up. Different measures are particu-
larly targeting various major events of obesity, primary
or secondary complications and comorbidities. New clini-
cal parameters that could offer more individualized and
patient orientated from perspective of efficiency are be-
ing studied widely.
Treatment of Obesity
Croatian physicians’ chamber initiated organization
of Croatian Obesity Society in 2002, with 4 congresses
(2002, 2006, 2008, 2010) giving Recommendations on di-
agnosing and treating of obesity in form of national
consensus14 (Table 1).
National plan for prevention and treatment of Obe-
sity and weight reduction was initiated by Ministry of
Health and Social Welfare in 200715.
Treatment of obesity is complex and enrolls multiple
clinical specialties (internal medicine, gastroenterology,
endocrinology, surgery, nutrition and psychology). Clini-
cal objective of medical treatment(s) should be focused at
a sustained 5–10% weight loss in order to prevent and re-
duce cardiovascular risks16 or other secondary complica-
tions of obesity17.
First steps enroll noninvasive methods and change of
life style in manner of regular strenuous physical activity,
reduced calories diet, and eventually by adding phar-
macotherapy (orlistat, sibutramin). Upon failure of con-
servative treatments (in 90–95%) patients are left with
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TABLE 1
RECOMMENDATIONS ON DIAGNOSING AND TREATING OF OBESITY
Therapy BMI 25–26.9 BMI 27–29.9 BMI 30–34.9 BMI 35–39.9 BMI >40
Diet, physical activity,
behavioral therapy
With cardiovascular
risk factor
With cardiovascular
risk factor
Yes Yes Yes
Pharmacotherapy With comorbidity
of obesity
Yes Yes Yes
Intragastric balloon (BIB) With comorbidity
of obesity
Yes Yes
Surgery With comorbidity
of obesity
Yes
possibilities with more invasive methods according to
their health condition and class of obesity (Table 1).
The most efficient therapy for lessening body weight
seems to be bariatric surgery. Bariatric procedures are
generally indicated for morbidly obese (BMI>40) and
superobese individuals (BMI>50) respectively, since tho-
se are burdened with greater complications on a natural
course. Ameliorative effects on major comorbidities sec-
ondary to obesity were well documented in prolonged fol-
low up of 10 years post bariatric surgery18.
Minimally invasive non surgical methods on the other
are acquiring attractiveness more and more. Endoscopic
implantation of intragastric balloon reduces volume of
ingested food i.e. total reduction of caloric intake, causes
space occupying fill effect with additional neurohumoral
changes that are being investigated currently. Studies
from minimally invasive endoscopic procedures also re-
port on ameliorated metabolic profile as significant treat-
ment effect19–22.
Due to pandemic growth of obesity and modest total
treatment success additional investigations are being
taken. Those are mostly concentrated around patophy-
siologic moments and genetic background with exploring
potential clinical use of at least couple dozens of pharma-
cological substances23–27. Preclinical animal studies are
investigating anti-ghrelin vaccine28,29, so far burdened
with relative inefficiency due to host response on gener-
ated autoantibodies. Since ghrelin is found likewise in
central nervous system and heart, beside gut and adipose
tissue, anti-ghrelin effects of treatment might cause pleio-
tropic unwanted sideeffects. Investigations came some-
what further with diacylglycerol acyl transferase-1
(DGAT1) inhibitors, which are now being teted for obe-
sity and diabetes in phase II clinical studies30.
History of Intragastric Ballons
Implantation of intragastric balloons is conceptually
simple method of obesity treatment. Weight loosing ef-
fect was observed to a large extent earlier in patients
with bezoars31. First therapeutic implantation of space
engaging device was reported in 1980 by Neiben32. Since
then wide range of balloons regarding volume, material,
filling etc (Table 2). Two earliest balloons were The
Garren-Edwards (GEGB) and the Ballobes. Garren Ed-
wards are 220 mL air filled plastic container looking like
tin, with sharp edges and was implanted for 3 months.
Those were introduced in the United States in 1985. and
remarkable 25.000 were implanted in period of couple of
years, when they were pulled off the market by FDA due
to relative inefficiency and complications (decubital ul-
cers (3–14%), erosions (26%), Mallory-Weiss (11%), defla-
tions (31%). Ballobes were rubber ballons, with an air-
-tight valve, upon insertion was inflated with 450 cm3 of
air (Table 2).
Following the world trends the series of intragastric
air filled rubber balloons were implanted in »Sestre
Milosrdnice« University Hospital Center among first in
this region and Croatia in 1991. A new generation liquid
filled balloons (The Bioenterics) were employed on from
2007.
Present Intragastric Ballons
Since a large scale of complications and technical is-
sues was noticed with first intragastric balloons in de-
spite their proven effectiveness, a scientific conference
was held in Tarpon, Springs, Florida in 1987. It was a
team of 75 experts liaised with obesity treatment from
various backgrounds as gastroenterologists, surgeons,
psychologists and general physicians. Recommendations
were given that therapeutic intragastric balloons should
hold certain characteristics (Table 3).
Over 10 000 liquid filled balloons (Bioenterics Intra-
gastric Balloon (BIB)) were implanted until recently and
series published in literature. On the other hand there
are just a few studies regarding two lately existing air
filled devices Heliosphere Bag and Endogast33,34 so they
will not be included in this review.
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TABLE 2
THE PRINCIPAL CHARACTERISTICS OF INTRAGASTRIC BALLOONS THROUGH HISTORY
Garren-Edwards Ballobes Taylor Wilson Cook BioEnterics
Shape Cylindrical Oval Oval Oval Spherical
Matherial Elastomer Elastomer Silicone Elastomer Silicone
Filling Air Air Fluid Air Fluid
Volume 250 mL 500 mL 500 mL 300 mL 500–600 mL
Reference Lindor 1987 Ramhamadany 1989 Marshall 1990 Mathus Vliegen 1990 Galloro 1999
TABLE 3
RECOMMENDATIONS REGARDING INTRAGASTRIC BALLOONS
CHARACTERISTICS FROM CONFERENCE IN TARPON, SPRINGS,
FLORIDA IN 1987
Targeted characteristics of intragastric balloons
Effectiveness in promoting weight loss
Filled with liquid (not air)
Capability of adjustment to various sizes
With smooth surface and low potential for causing erosions,
ulcers or obstructions
Marked with radiopaque marker that allows proper follow up
e.g. the device if it deflates
Constructed of durable materials that do not leak
Bioenterics Intragastric Balloon (BIB)
The BIB is endoscopic intragastric balloon used as
method for obesity treatment by achieving restriction in-
take of food. It is spherical, saline-filled intragastric de-
vice filled with fluid and designed for nonsurgical treat-
ment of obesity and morbid obesity35. Second generation
of BIB (onwards 2000) was made smooth surface durable
elastic silicone, with a fill range of 400–800 mL of physio-
logical saline colored with methylene-blue (Figure 2).
The BIB is routinely implanted following certain indi-
cations (Table 4) under conscious sedation or exception-
ally in total anesthesia. Procedure begins as upper diag-
nostic gastroscopy and if there are no abnormalities or
local contraindications present, placement in stomach is
done under endoscopic guidance. Balloon is filled with
sterile saline (cca 400–800 mL) and 10 mL of methylene
blue through attached small filling tube catheter. Once
the device is filled the operator pulls out the catheter, and
balloon is left floating freely in the stomach (Figure 3).
Position of BIB is controlled by transabdominal ultra-
sound (Figure 4), native abdominal radiograph or by con-
trol upper gastrointestinal endoscopy.
During short postimplantation period patients re-
ceive parenteral fluid and symptomatic therapy in order
to cover gastric hypersensitivity and adaptation on bal-
loon presence. First three days are the most commonly
burdened with complications as dyspepsia, vomiting, ab-
dominal cramps. Pharmacological treatment includes pro-
ton pump inhibitors, metoclopramide, scopolamine bu-
tylbromide. Patients are discharged after normal peroral
liquid nutrition is tolerable. A proton pump inhibitors
are mandatory during complete implantation treatment
period influencing protective both for gastric mucosa and
balloon surface20.
BIB is inserted in stomach for 6 months and patients
receive BIB identification card (Figure 5). Patient is fol-
lowed by gastroenterologist routinely in time periods
from 1–3 months. Routine outpatient control includes
abdominal ultrasound, anthropometrics, and blood che-
mistry laboratory exams.
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TABLE 4
INDICATIONS AND CONTRAINDICATIONS FOR INTRAGASTRIC
BALLOON TREATMENT
Recommended indications
BMI<35 with comorbidities and resistance to conservative
treatment
BMI >35 with resistance to conservative treatment and re-
fusal or present contraindication to surgical treatment
BMI >50 super-obese individuals with very high operative
risk as preparation of further surgery
BIB test- evaluation and selection of patients for restrictive
procedures
Reduction of anesthetic risk (all surgery)
Absolute contraindications
Previous gastric surgery
Hiatal hernia >5 cm
Coagulation disorder
Potentially bleeding lesion of the upper gastrointestinal tract
Pregnancy or desire to become pregnant, breast feeding
Drugs/alcohol abuse
Obesity of secondary origin (hormonal, genetic)
Malignancy within 5 years
Drugs/alcohol abuse
Severe liver disease
On active treatment of obesity with pharmaceuticals
Any contra-indication to endoscopy
Relative contraindications
Previous abdominal surgery
Active gastritis, H pylori infection, duodenal ulcers
Hiatal hernia <5 cm, mild esophagitis
Severe esophagitis (class III and IV)
Hemorrhage from upper gastrointestinal system
Nonsteroidal antiinflammatory drugs, anticoagulants and
antiaggregators
Crohn’s disease
Psychiatric illness
Malformations of esophagus or larynx
Inflammatory bowel diseases
Fig. 1. First series of intragastric balloons implanted in »Sestre Milosrdnice« University Hospital Center (formerely Mladen Stojanovic)
20 years ago; a) native abdominal X-ray, b) radiology report.
Before removal patient must be kept on a liquid diet
for 1 day. Removal is done by upper gastrointestinal en-
doscopy. After diagnostic examination of mucosa and bal-
loon, punctuation is done with needle. Containing fluid is
completely drained through catheter connected to pump
with negative pressure. Extraction is done by foreign
body grasper.
Experiences with Bioenterics Intragastric
Balloons
Since the first generation of BIB was developed in
1998, and enhanced in 2001 year it was outspread within
the world. Series of patients consider it quite popular be-
cause is simple, minimally invasive, with short inser-
tion/removal duration and is effective form of obesity
treatment.
BIB intragastric balloon treatment analyses of clini-
cal series showed the most optimal outcomes in patients
within BMI range 35 to 4019. Is also found to be very effi-
cient in the short term as a treatment modality for mor-
bidly obese (BMI >40) and superobese (BMI>50) pa-
tients reducing constitutive preoperative risks of general
or bariatric surgery.
Weight Loss Effect of BIB Treatment
Up to date there is avalilable over 160 studies, of
which 30ish were used multiple times in meta analy-
ses36,37. Meta analysis from 22 studies with 4371 patients
reported mean weight loss on BIB 17.8 kg (4.9–28.5 kg),
but with immense differences among studies37. A ran-
domized crossover trial showed difference of 12 kg within
group placebo and balloon38.
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Fig. 2. BIB intragastric balloon (BIB, Inamed Health, Santa
Barbara, CA, USA).
Fig. 3. Upper gastrointestinal endoscopy: different stages of bal-
loon implantation.
Fig. 4. Transabdonimal ultrasound (t-USD) control of balloon’s
position and morphology i.e. fuction.
Fig. 5. BIB – patient identification card.
Weight loss among studies has a propensity to be su-
perior in patients with greater BMI (22 kg with BMI >40
and 12 kg in BMI <40). On the other hand, when consid-
ering the percentage of excess weight loss, better results
were reported with patients that had lesser BMI (non-
-morbid obesity) and smaller % EWL37. Standard intra-
gastric balloon treatment lasts for 6 months, although
major of percentage weight loss was reported within first
3 months (48.6%) in compare to completed 6 months pe-
riod (50.83%)39. However these observations need fur-
ther clarifications in regard to hormonal change, influ-
ence on obesity comorbidities and long term follow up
with weight regain. Report from Italy by Genco et al.21
included remarkable 2515 patients and showed average
decrease of 5 BMI units, with largest weight loss of 9 BMI
with preoperative morbidly obese patients (Table 5).
Reproducibility and Comparability among
Studies
Significant deal of published studies could not be com-
pared fairly due to different settings. In a report by
Ganesh et al. from Singapore40, treatment with intragas-
tric balloons gained less efficiency in Asian individuals,
which might partially be due to different anthropometric
parameters, particularly because of lower volume of bal-
loon filled, lower volume capacity of stomach and signifi-
cantly greater intolerance rates with premature removal.
Conversely, in a report from Ohta et al.41 on 21 obese pa-
tient results from similar settings regarding population
gave 12±5kg, and 27±9% (% LTW) which is pairing to our
series and other reports on Caucasians36,37,42 which mi-
ght bring additional point for clarification. Study from 6
clinics with private medical care and the second biggest
study published so far by Sallet et al., and reported %
EWL of 48.3±28.120. Although outcomes were superior
than average from meta-analyses36,37,42 due to inclusion
of substantial share of addressees with from morbidly
obese group that are better candidates for bariatric sur-
gery. In despite to more efforts made around follow up
only a third of patients were finally included in analyses,
which might be dubious for reproducibility.
Long Term Weight Loss and Maintenance
with BIB Treatment
Concrete effects on comorbidity with BIB treatment
with sustained responses should be judged in prolonged
follow up period longer than one year via Herve et al.22,
to assess real significances37.
There are several available studies (Table 6) in regard
to prolonged follow up of patients with intragastric bal-
loon treatment. Maintenance of weight loss after balloon
treatment was reported in 8 studies, of which 3 had fol-
low up period of one year with 28–40% return of the total
lost weight36,37.
In a study by Dumonceau et al. in a prolonged follow
up of 5 years whole tested population had lost a median
of 2.0 kg or 6.2 %EWL. Significant treatment effect
(>or=10% baseline weight loss) was some better with
bariatric surgery (32%) than BIB (26%)43. Interestingly
repeated BIB treatment had no relation to proportions of
subjects with sufficient baseline weight loss or bariatric
surgery.
Dastis et al. reported 100 patients with average follow
up 4.8±1.6 years, with 3% dropout44. At 6 months treat-
ment i.e. BIB removal average weight loss was 12.6±8.3
kg, 63 individuals with > or =10 % baseline weight loss.
Weight regain was 4.2±6.8 in first year post-BIB and
2.3±6.0 kg in second. At 36 months after BIB, treatment
was efficient with 24 participants. Nearly one third of pa-
tient had over 10% LTW, and 35 took bariatric surgery
mostly due to weight gain over half in compare to initial
BMI.
Sallet et al.20 presented series of 323 patients from
Brazil treated for 6-months treatment with 1 year follow
up with significant outcomes, which might partially be
due to different motivation of patients, regarding it was
performed in private clinics. There was noted a signifi-
cant change in body weight reduction (15.2–10.5 kg), %
of excess weight loss (48.3±28.1), BMI (–5.3±3.4 kg/m2),
while 85 of patients remained 90% of their BMI reduced
with intragastric balloon-treatment. There was also ob-
served excellent effect on reducing of obesity related
comorbidities in over ¾ of treated individuals, with reso-
lution or improvement of hyperlipoproteinemia as one
among the most influential cardio/neurovascular risk
factor in bit over half of patients. However, probably due
to biometrical differences among patients in series from
Singapore by Ganesh et al.40 treatment for obesity with
intragastric balloons was seen as insufficiently efficient
with maximal weight loss 5.9 kg (1.4–13.4), % of excess
weight loss 32.4% (6.7–87). What is more important, af-
ter the 1 year follow up mean weight loss compared to
pre-BIB was 1.5kg, mean % of excess weight loss 10.9%
(15.1–31.3), with only 20% of 20 patients were overall
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TABLE 5
WEIGHT LOSS WITHIN STUDIES
Age BMI Change /kg Change BMI Change % EWL
Non morbid obesity – 5 studies N 665 33–37.5 31–39 9.5–18.6 5.3–5.7 38.1–50.8
Morbid obesity – 5 studies N=573 31–43 41–46.6 13–15 4.8–5.3 18.7–35.0
Preoperative wight loss 2 – studies N=58 38.8–43.3 58.4–60.2 18.1–26.4 6.4–9.4 21–26.1
Genco et al. N=2515 38.9 44.4 4.9 33.9
satisfied with treatment. Through a few of studies re-
treatment showed not to be efficient as nascent BIB
treatment.
Post BIB treatment long term follow up outcomes
vary even more and are indeed difficultly for comparison
or drawing more solid conclusions, so additional points
as including endocrinology part might be the necessity.
Metabolic and Endocrine Effects of BIB
Treatment
During BIB is implanted a hormonal changes as de-
crease in plasma leptin and a transient elevation of
plasma ghrelin45, without changes in adiponectin46. In-
tragastric balloon treatment beyond primer weight loo-
sing effects offers significant alleviation of endocrinolo-
gic comorbidities of obesity, as follows: diabetes (54.4%),
hypertension (48.9%), osteoarthritis (46.1%), hyperlipo-
proteinemia (36.5%)21 and liver steatosis47.
Obesity is closely related with multiple hormonal dis-
turbances, which are not fully understood with respect to
primary origin. The optimal time-line and criteria for as-
sessing secondary effects in relation to post BIB-treat-
ment still have not been defined or concerned unani-
mously.
Complications and Safety of BIB Treatment
Meta analysis of 16 trials on a sample of 3429 balloons
(Table 7) reported by Imaz et al.42 noted complications as
follows: Nausea / vomiting after first week 8.6%, Abdom-
inal pain and minor digestive disorders 5.0%, Defla-
tion/displacement 2.5%, Inflammation or lesion in diges-
tive lining 2.1%, Gastro-esophageal reflux 1.8%, Dehidra-
tion 1.6%, Deflation without displacement of the balloon
0.9%, Obstruction in the digestive tract 0.8%, Diarrhea /
constipation 0.7%, Gastric ulcer 0.4%, l Gastric perfora-
tion 0.1%, Mortality related to balloon treatment (perfo-
ration of stomach) 0.1%. Early removal of balloon was
detected in 4.2% of patients (143/3442), of which 43%
were voluntary procedures. Regarding safety of BIB treat-
ment (table 8) in a meta analyses by Vieglen et al. that in-
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TABLE 7
COMPLICATIONS OF BIB TREATMENT
Reports 1999–2006 Ezophagitis
Esophageal
erosions
Gastric ulcer Gastric erosions
Gastric
perforation
Mortality
16 studies; N=1402
n 62 10 12 7 3 0
% 4.4 0.71 0.86 0.5 0.2 0
Genco et al. N=2515
n 32 5 5 2
% 1.27 0.2 0.2 0.08
TABLE 6
BIB TREATMENT FOLLOW UP
N-start
BIB
Weight loss
Control period
without BIB
N-control Weight regain
Non morbid obesity
Sallet et al. 323 48.3% EWL 6 months 85 +6.5 % EWL
Herve et al. 100 12 kg 12 months 100 +3.4 kg; 56 remained
Morbid obesity
Doldi et al. 132 14.4 kg 6 months 38 14–7.8 kg; 17 + 8.4 kg; 7 remained
Loffredo et al. 64 14.3 kg 6 months 34 28+5.5 kg; 4 start; 2 remained
Mathus-Vliegen 43 21.3 kg 12 months 43 +8.6 kg
33 25.6 kg 12 months 33 +11 kg
Negrin Dastis et al.
100
Non morbid obese 86%
Morbidly obese 14%
12.6±8.3 kg 36 months 98
Regain 4.2±6.8, (18months)
Regain 2.3±6.0 kg (30months)
24 % remained with LTW>10% at
36 months
Preoperative loss of kg
Weiner et al. 15 18.1 kg 1 months 15 +2.4 kg
Busetto et al. 43 26.4 kg 1 months 43 +1.6 kg
cluded 4037 patients deflation occurred in 8.1% (123/
1522)36. Immense series21 also observed particular co-
morbidities as previous gastric surgery, hiatus hernia
and gastritis/severe esophagitis that were all linked to
major complications (generally in need for surgery) lin-
ked to intragastric balloon treatment. Majority were
evacuated per rectum in 70.7% (87 balloons) while only
25.2% (31 balloon) were extracted from the stomach,
with emergency surgical removal in 4.1% (n=5). Life
threatening risks requiring an operation occurred in 5
patients from 4037.
Need for early removal due to substantial subjective
intolerance occurred in 6.7%36. Gastrointestinal compli-
cations present in 5.5% could be treated conservatively,
except for perforations (n=3). Balloon deflation rate was
8.1% generally without additional complications.
Quality of Life
We earlier reported of the relationship regarding in-
tragastric balloon treatment effect on weight loss in
manner of patients’ treatment satisfaction19. Although
subjectively expected this difference in health quality
were not earlier described as typical39. However, it could
be interest category for including in future studies from
the similar backgrounds.
There are still quite some lacks available with ques-
tionnaires in regard to separating quality of life changes
in relation to obesity48,49, its commorbidities50 treatment
and posttreatment periods.
Treatment Failure and Related Parameters
A therapeutic difference of %LTW <10 is considered
as a treatment failure. Genco et al. defined a successful
weight loss being at least 20% of excessive weight loss,
with a failure rate of 15% treated21. Additional psycho-
logical assessment prior to treatment might offer benefit
regarding excluding individuals with binge eating disor-
der, or transferring those to different protocols for since
they showed to obtain lesser BMI with intragastric bal-
loons with loss 3.3 vs. 5.7 in non-binge controls51. Indi-
viduals with non-morbid obesity generally have higher
usefulness of BIB treatment, on the origin of the % EWL,
attributable to the fact that comparable AWR repre-
sented a greater difference in BMI. Morbidly obese pa-
tients on BIB treatment have paradoxically similar AWR
and % LTW. Greatest part (90%) of patients with BMI40
have associated metabolic syndrome and represent be-
tter candidates for bariatric surgery. Candidates from
morbidly and super-obese groups who had success with
BIB treatment mostly do not agree to take recommended
surgery19. Substantially more efforts must be applied
with patients that do not comply to bariatric surgery or
have contraindication, in order to gain clinically signifi-
cant achievement particularly around medical history,
continuous psychological and nutritionist support. This
is important in both prior treatment and during follow
up periods.
The Position of Intragastric Ballon Therapy
for Treatment of Obesity
Intragastric balloons are a valuable minimally inva-
sive endoscopic therapy option for treatment of obesity
between pharmacotherapy and surgery. BIB intragastric
balloon treatment showed to offer the best gains with in-
dividuals ranging BMI from 35 to 4019. Even though
timeline efficiency drops from 85% at 6 months to 24% at
36 months, it offers substantial positive influence on
comorbidities (over 50%), particularly cardiovascular risk
factors, altering for the better quality of life37,44. BIB
treatment is also efficient but transient modality of treat-
ment in morbidly obese and superobese individuals to re-
duce preoperative risk on general and bariatric surgery.
Obesity treatment with BIB is well tolerated and safe, of-
fering better quality of life.
There are great variances among general obesity treat-
ment or appliance of intragastric balloons. In this man-
ner further studies that would define new clinical param-
eters reproducible for treatment resistance in order to
provide resourcefully individualized therapy. One must
not forget the ameliorative influences of lifestyle changes
and implementation of physical activity, particulary in
relation to obesity52.
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TABLE 8
BIB TREATMENT SAFETY
Reports 1999–2006 Deflation
Endoscopic removal
from stomach
Rectal evacuation Emergency surgery Difficult removal
16 studies; N=1402
N 123 (8.1%) 31 87 5 9
% 25.2 70.7 4.1 0.64
Genco et al. N=2515
N/% 9 (0.36%) 9 (100%)
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POZICIJA INTRAGASTRI^NIH BALONA U GLOBALNOJ INICIJATIVI LIJE^ENJA PRETILOSTI
S A @ E T A K
Debljina je kroni~na bolest s vi{estrukim u~incima za zdravstveno stanje pojedinca i me|u najva`nijim zdravstve-
nim problemima dana{njice. Prema javnozdravstvenim podacima oko 65% populacije Hrvatske je preuhranjeno, a od
toga oko 20% pretilo. Hrvatska lije~ni~ka komora u suradnji s Ministarstvom Zdravstva i socijalne skrbi izdali su smjer-
nice o dijagnostici i lije~enju debljine u obliku nacionalnog koncenzusa. Lije~enje debljine je kompleksan problem i
uklju~uje vi{e klini~kih struka. Promjena `ivotnih navika, energi~na tjelesna aktivnost i farmakoterapija dio su konzer-
vativnog lije~enja. Djelotvorniji se rezultati posti`u primjenom barijatrijske kirurgije ili minimalno invanzivnih endo-
skopskih zahvata, koji se propisuju obzirom na po~etni indeks tjelesne mase (ITM). Ugradnja intragastri~nih balona
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predstavlja konceptualno jednostavan princip lije~enja debljine. Suvremeni intragastri~ni baloni od kojih je najzastup-
ljeniji BioEnterics-ov(BIB®) (Inamed Health, USA) postaju sve popularniji me|u bolesnicima i lije~nicima. BIB nudi
najbolje rezultate za pojedince sa ITM od 35–40. U~inkovitost intragastri~nih balona pokazuje vremensku zavisnost od
85% nakon 6-mjese~nog tretmana do 24% nakon pra}enja od 36 mjeseci. BIB pobolj{ava stanje komorbiditeta debljine,
pogotovo kardiovaskularnog rizika. Lije~enje BIB-om tako|er je djelotvorno, ali samo kao privremen oblik lije~enja
morbidno i super pretilih osoba na na~in da smanjuje perioperativni rizik za predstoje}u barijatrijsku ili op}u kirurgiju.
Lije~enje debljine uz pomo} BIB-a je djelotvorno, dobro podno{ljivo, sigurno i nudi bolju kvalitetu `ivota. Ukupni rezul-
tati konzervativnih oblika lije~enja debljine mogu se smatrati nezadovoljavaju}im na dulji rok, te su potrebna nova
istra`ivanja za identifikaciju dodatnih klini~kih parametara rezistencije. Kako bi se ponudio u~inkovit, prema bolesni-
ku individualiziran terapijski pristup suvremena istra`ivanja vi{e su fokusirana na endokrinolo{ke stavke debljine.
Hormonalni u~inci BIB lije~enja, te usporedba prema barijatrijskoj kirurgiji su potencijalno interesantni za budu}a
istra`ivanja.
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